| Article
In a guide for team physicians working with young athletes—10 to 18 years old—it is recommended that practitioners look at all factors involved before potentially prescribing opioids to this age group. This Special Communications: Team Physician and Consensus Statement appears in the journal Medicin...
| Article
New guidelines and recommendations from the American College of Physicians and American Academy of Family Physicians are outlined in Annals of Internal Medicine. Specifically, the guidelines examine how best to combat adult acute pain from musculoskeletal injuries via both pharmacologic and...
| Article
The burden of chronic pain on the person who experiences it daily is evident. What about the partner or caregiver of the patient? In a study in the European Journal of Pain, new insights are offered into household partnerships. What is needed is additional information that “might provide empirical...
| Article
The American Heart Association has issued a scientific statement calling for education for clinicians on the health implications of cannabis products. They are calling for funding and clinical trials, both of which are predicated on the removal of legal hurdles. The AHA states, “Our understanding of...
| Article
A poster abstract (LB008) presented at the American Academy of Pain Medicine 36th Annual Meeting acknowledges the potential of sweat as a biofluid alternative for drug testing. The abstract states that, although used extensively, “sampling of urine is inconvenient, tamper prone, and results are...
| Article
England’s NICE—the National Institute for Health and Care Excellence—is advising that other types of pain management/treatment should be utilized before common pain medications. Nonpharmacologic suggestions include exercise, psychotherapy, acupuncture, and electrical modalities. In its draft...
| Article
The American Medical Association just released a new OPIOID TASK FORCE 2020 PROGRESS REPORT in the hopes of reducing drug overdoses and deaths. Although prescription opioid overdose deaths have decreased, illicit drugs such as heroin, methamphetamine, and cocaine have risen. Last year, fentanyl...
| Article
“Even during this global pandemic, we have continued to prioritize addressing the opioid crisis,” says Stephen M. Hahn, MD, the FDA’s Commissioner, referring to the FDA’s new labeling requirement. This labeling—on opioid pain medication and opioid use disorder medication—must include the...
| Article
From the American Journal of Psychiatry.
Abstract
Objective: Given changes in U.S. marijuana laws, attitudes, and use patterns, individuals with pain may be an emerging group at risk for nonmedical cannabis use and cannabis use disorder. The authors examined differences in the prevalence of...
| Article
From NEJM Catalyst.
While Covid-19 has rightly grabbed the attention of health care organizations and policymakers, other health care challenges, like the opioid crisis, persist under the radar. Many people continue to suffer from poorly managed pain, and, in fact, may face additional challenges...